Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex(R) Biliary RX Stent

By Boston Scientific Corporation, PRNE
Thursday, October 21, 2010

Company's Fully Covered Metal Stent Now Approved for Use in Treating Benign Biliary Strictures

NATICK, Massachusetts, October 22, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced that
its WallFlex(R) Biliary RX Fully Covered Stent has received CE Mark approval
for the treatment of benign biliary strictures.

"The WallFlex Biliary RX Fully Covered Stent has proved
effective in the management of malignant biliary strictures, and I'm pleased
that physicians in Europe and other CE Mark countries can now use this stent
to treat benign biliary strictures," said Professor Jacques Deviere, M.D.,
Ph.D., Hôpital Erasme in Brussels. "The WallFlex Stent incorporates the
latest innovations in self-expanding metal stent technology and may provide
significant benefits as a less-invasive alternative to surgery in these

"This new indication gives me the confidence to perform what I
have found to be the most effective therapy - metal stent placement - during
the initial ERCP[1] procedure in patients where previously I would have
waited for a confirmed diagnosis of the stricture," said Adrian Hatfield,
M.D., University College London Hospital. "It may help to reduce the number
of procedures my patients must undergo, while containing costs and providing
the best possible care."

The WallFlex Biliary RX Stent is constructed of braided,
Platinol(TM) (platinum-cored Nitinol) wire and features three key attributes:
radial force to help maintain duct patency and resist migration, flexibility
to aid in conforming to tortuous anatomies, and full-length radiopacity to
enhance stent visibility under fluoroscopy. The WallFlex Biliary RX family of
stents is available in fully covered, partially covered and uncovered
versions. The covered stents have a silicone polymer Permalume(R) coating
designed to reduce the potential for tumor/tissue ingrowth, and an integrated
retrieval loop for removing or repositioning the stent in the event of
incorrect placement during the initial procedure or for removal up to 12
months following initial placement in benign strictures for the fully covered

"The WallFlex Biliary RX Stent leverages existing Boston
Scientific technologies, while advancing performance with new features based
on physician feedback," said Michael Phalen, Senior Vice President, and
President of Boston Scientific's Endoscopy Division. "With our full line of
WallFlex Biliary, Enteral and Esophageal Stents, Boston Scientific offers the
most comprehensive range of innovative treatment options to diagnose,
palliate and treat patients with diseases of the gastrointestinal tract."

The complete line of WallFlex Biliary RX Stents — Fully
Covered, Partially Covered and Uncovered — have previously received CE Mark
and FDA clearance for the palliative treatment of malignant biliary
strictures. The WallFlex Stent is the most frequently implanted biliary metal
stent worldwide.

Boston Scientific at UEGW

The WallFlex family of self-expanding metal stents will be
available for hands-on demonstration at the United European Gastroenterology
Week (UEGW), October 23 - 27 in Barcelona.

Boston Scientific will host a symposium titled "Controversies
in Biliary Stenting," chaired by Professor Guido Costamagna, M.D.,
Policlinico Gemelli, Rome, which will take place on October 27 from 7:00 -
8:00 a.m.
(local time) in the CCIB Congress Center, Room 112, Level 1. The
symposium will include the following presentations:

- "Stenting for Benign Biliary Strictures: Whether, What and
When?" by Professor Horst Neuhaus, M.D., Evangelisches Krankenhaus,

- "Preoperative Therapy and Stenting: A Surgeon's
Perspective," by Professor Mustapha Adham, M.D., Hôpital Edouard Herriot,

- "A Metal Stent for Every Extrahepatic Biliary Stenosis?" by
Professor Thierry Ponchon, M.D., Hôpital Edouard Herriot, Lyon

The WallFlex Biliary RX Fully Covered Stent is not approved in
the U.S. for the treatment of benign biliary strictures. The safety and
effectiveness of the WallFlex Biliary RX Stent System for use in the vascular
system have not been established.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for
less invasive, more efficient gastrointestinal procedures.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance,
competitive offerings and market position. If our underlying assumptions turn
out to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT:   Geraldine Varoqui
               Director International Public Relation
               Tel: +49-2102-489-461
               Mob: +49-170-782-85-58


    [1] Endoscopic Retrograde Cholangiopancreatography

Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig at

will not be displayed